898 related articles for article (PubMed ID: 26751635)
1. Safety and Clinical Effects of Mesenchymal Stem Cells Secreting Neurotrophic Factor Transplantation in Patients With Amyotrophic Lateral Sclerosis: Results of Phase 1/2 and 2a Clinical Trials.
Petrou P; Gothelf Y; Argov Z; Gotkine M; Levy YS; Kassis I; Vaknin-Dembinsky A; Ben-Hur T; Offen D; Abramsky O; Melamed E; Karussis D
JAMA Neurol; 2016 Mar; 73(3):337-44. PubMed ID: 26751635
[TBL] [Abstract][Full Text] [Related]
2. NurOwn, phase 2, randomized, clinical trial in patients with ALS: Safety, clinical, and biomarker results.
Berry JD; Cudkowicz ME; Windebank AJ; Staff NP; Owegi M; Nicholson K; McKenna-Yasek D; Levy YS; Abramov N; Kaspi H; Mehra M; Aricha R; Gothelf Y; Brown RH
Neurology; 2019 Dec; 93(24):e2294-e2305. PubMed ID: 31740545
[TBL] [Abstract][Full Text] [Related]
3. Phase I trial of repeated intrathecal autologous bone marrow-derived mesenchymal stromal cells in amyotrophic lateral sclerosis.
Oh KW; Moon C; Kim HY; Oh SI; Park J; Lee JH; Chang IY; Kim KS; Kim SH
Stem Cells Transl Med; 2015 Jun; 4(6):590-7. PubMed ID: 25934946
[TBL] [Abstract][Full Text] [Related]
4. Biological markers of mesenchymal stromal cells as predictors of response to autologous stem cell transplantation in patients with amyotrophic lateral sclerosis: an investigator-initiated trial and in vivo study.
Kim HY; Kim H; Oh KW; Oh SI; Koh SH; Baik W; Noh MY; Kim KS; Kim SH
Stem Cells; 2014 Oct; 32(10):2724-31. PubMed ID: 24966156
[TBL] [Abstract][Full Text] [Related]
5. Transplantation of Mesenchymal Stromal Cells in Patients With Amyotrophic Lateral Sclerosis: Results of Phase I/IIa Clinical Trial.
Syková E; Rychmach P; Drahorádová I; Konrádová Š; Růžičková K; Voříšek I; Forostyak S; Homola A; Bojar M
Cell Transplant; 2017 Apr; 26(4):647-658. PubMed ID: 27938483
[TBL] [Abstract][Full Text] [Related]
6. A randomized placebo-controlled phase 3 study of mesenchymal stem cells induced to secrete high levels of neurotrophic factors in amyotrophic lateral sclerosis.
Cudkowicz ME; Lindborg SR; Goyal NA; Miller RG; Burford MJ; Berry JD; Nicholson KA; Mozaffar T; Katz JS; Jenkins LJ; Baloh RH; Lewis RA; Staff NP; Owegi MA; Berry DA; Gothelf Y; Levy YS; Aricha R; Kern RZ; Windebank AJ; Brown RH
Muscle Nerve; 2022 Mar; 65(3):291-302. PubMed ID: 34890069
[TBL] [Abstract][Full Text] [Related]
7. A phase II clinical trial with repeated intrathecal injections of autologous mesenchymal stem cells in patients with amyotrophic lateral sclerosis.
Petrou P; Kassis I; Yaghmour NE; Ginzberg A; Karussis D
Front Biosci (Landmark Ed); 2021 Oct; 26(10):693-706. PubMed ID: 34719198
[No Abstract] [Full Text] [Related]
8. The immunomodulatory effects of human mesenchymal stem cells on peripheral blood mononuclear cells in ALS patients.
Kwon MS; Noh MY; Oh KW; Cho KA; Kang BY; Kim KS; Kim YS; Kim SH
J Neurochem; 2014 Oct; 131(2):206-18. PubMed ID: 24995608
[TBL] [Abstract][Full Text] [Related]
9. miRNA profiling of NurOwn®: mesenchymal stem cells secreting neurotrophic factors.
Gothelf Y; Kaspi H; Abramov N; Aricha R
Stem Cell Res Ther; 2017 Nov; 8(1):249. PubMed ID: 29116031
[TBL] [Abstract][Full Text] [Related]
10. Repeated Intrathecal Mesenchymal Stem Cells for Amyotrophic Lateral Sclerosis.
Oh KW; Noh MY; Kwon MS; Kim HY; Oh SI; Park J; Kim HJ; Ki CS; Kim SH
Ann Neurol; 2018 Sep; 84(3):361-373. PubMed ID: 30048006
[TBL] [Abstract][Full Text] [Related]
11. Safety of intrathecal autologous adipose-derived mesenchymal stromal cells in patients with ALS.
Staff NP; Madigan NN; Morris J; Jentoft M; Sorenson EJ; Butler G; Gastineau D; Dietz A; Windebank AJ
Neurology; 2016 Nov; 87(21):2230-2234. PubMed ID: 27784774
[TBL] [Abstract][Full Text] [Related]
12. Effect of mesenchymal stromal cell transplantation on long-term survival in amyotrophic lateral sclerosis.
De Marchi F; Mareschi K; Ferrero I; Cantello R; Fagioli F; Mazzini L
Cytotherapy; 2023 Aug; 25(8):798-802. PubMed ID: 36931995
[TBL] [Abstract][Full Text] [Related]
13. Safety and immunological effects of mesenchymal stem cell transplantation in patients with multiple sclerosis and amyotrophic lateral sclerosis.
Karussis D; Karageorgiou C; Vaknin-Dembinsky A; Gowda-Kurkalli B; Gomori JM; Kassis I; Bulte JW; Petrou P; Ben-Hur T; Abramsky O; Slavin S
Arch Neurol; 2010 Oct; 67(10):1187-94. PubMed ID: 20937945
[TBL] [Abstract][Full Text] [Related]
14. β-PIX is critical for transplanted mesenchymal stromal cell migration.
Koh SH; Huh YM; Noh MY; Kim HY; Kim KS; Lee ES; Ko HJ; Cho GW; Yoo AR; Song HT; Hwang S; Lee K; Haam S; Frank JA; Suh JS; Kim SH
Stem Cells Dev; 2012 Jul; 21(11):1989-99. PubMed ID: 22087847
[TBL] [Abstract][Full Text] [Related]
15. Safety of repeated transplantations of neurotrophic factors-secreting human mesenchymal stromal stem cells.
Gothelf Y; Abramov N; Harel A; Offen D
Clin Transl Med; 2014; 3():21. PubMed ID: 25097724
[TBL] [Abstract][Full Text] [Related]
16. Umbilical Cord Mesenchymal Stem Cells in Amyotrophic Lateral Sclerosis: an Original Study.
Barczewska M; Maksymowicz S; Zdolińska-Malinowska I; Siwek T; Grudniak M
Stem Cell Rev Rep; 2020 Oct; 16(5):922-932. PubMed ID: 32725316
[TBL] [Abstract][Full Text] [Related]
17. Protective effects of neurotrophic factor-secreting cells in a 6-OHDA rat model of Parkinson disease.
Sadan O; Bahat-Stromza M; Barhum Y; Levy YS; Pisnevsky A; Peretz H; Ilan AB; Bulvik S; Shemesh N; Krepel D; Cohen Y; Melamed E; Offen D
Stem Cells Dev; 2009 Oct; 18(8):1179-90. PubMed ID: 19243240
[TBL] [Abstract][Full Text] [Related]
18. Safety and efficacy of first-in-man intrathecal injection of human astrocytes (AstroRx®) in ALS patients: phase I/IIa clinical trial results.
Gotkine M; Caraco Y; Lerner Y; Blotnick S; Wanounou M; Slutsky SG; Chebath J; Kuperstein G; Estrin E; Ben-Hur T; Hasson A; Molakandov K; Sonnenfeld T; Stark Y; Revel A; Revel M; Izrael M
J Transl Med; 2023 Feb; 21(1):122. PubMed ID: 36788520
[TBL] [Abstract][Full Text] [Related]
19. The use of mesenchymal stem cells (MSCs) for amyotrophic lateral sclerosis (ALS) therapy - a perspective on cell biological mechanisms.
Tang BL
Rev Neurosci; 2017 Oct; 28(7):725-738. PubMed ID: 28599400
[TBL] [Abstract][Full Text] [Related]
20. Mesenchymal stem cells induced to secrete neurotrophic factors attenuate quinolinic acid toxicity: a potential therapy for Huntington's disease.
Sadan O; Shemesh N; Barzilay R; Dadon-Nahum M; Blumenfeld-Katzir T; Assaf Y; Yeshurun M; Djaldetti R; Cohen Y; Melamed E; Offen D
Exp Neurol; 2012 Apr; 234(2):417-27. PubMed ID: 22285250
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
